Human Recombinant Hexokinase 2 | 6308

Hexokinase is the first enzyme in the glycolytic pathway, catalyzing the transfer of a phosphoryl group from ATP to glucose to form glucose-6-phosphate and ADP. In vertebrates there are four major glucose-phosphorylating isoenzymes, designated hexokinase I, II, III, and IV This enzyme is found in most cells, but there is tissue specificity for the particular type of hexokinase. Hexokinase 2 is found in the skeletal muscle and includes hydrophobic N-terminal sequence capable of targeting the hexokinase to mitochondria. It also constitutes the principal regulated isoform in many other cell types and is increased in many cancers. Although found in NIDDM patients, genetic variations of HK 2 do not contribute to the disease.

6308 | Human Recombinant Hexokinase 2 DataSheet

Biomolecule/Target: N/A

Synonyms: Hexokinase type II, Muscle form hexokinase, HK2.

Alternates names: Hexokinase type II, Muscle form hexokinase, HK2.

Taglines: An enzyme that phosphorylates hexoses

NCBI Gene ID #: 16170

NCBI Gene Symbol: IL16

Gene Source: Human

Accession #: O54824

Recombinant: Yes

Source: E. coli

Purity by SDS-PAGEs: 98%

Assay: SDS-PAGE

Purity: N/A

Assay #2: N/A

Endotoxin Level: N/A

Activity (Specifications/test method): N/A

Biological activity: Specific activity is 3-4 units/ml obtained by measuring the increase of NADPH in absorbance at 340 nm resulting from the reduction of NADP.

Results: N/A

Binding Capacity: N/A

Unit Definition: In the coupled mode, one unit will produce 1.0 µmole of NADPH per minute as glucose is phosphorylated by ATP at pH 7.4 at 25°C.

Molecular Weight: 104.1 kDa

Concentration: 1 mg/ml

Appearance: Liquid

Physical form description: 1 mg/ml solution in 20 mM Tris-HCl buffer (pH 8.0) containing 10% glycerol.

Reconstitution Instructions: N/A

Amino acid sequence: MGSSHHHHHH SSGLVPRGSH MIASHLLAYF FTELNHDQVQ KVDQYLYHMR LSDETLLEIS KRFRKEMEKG LGATTHPTAA VKMLPTFVRS TPDGTEHGEF LALDLGGTNF RVLWVKVTDN GLQKVEMENQ IYAIPEDIMR GSGTQLFDHI AECLANFMDK LQIKDKKLPL GFTFSFPCHQ TKLDESFLVS WTKGFKSSGV EGRDVVALIR KAIQRRGDFD IDIVAVVNDT VGTMMTCGYD DHNCEIGLIV GTGSNACYME EMRHIDMVEG DEGRMCINME WGAFGDDGSL NDIRTEFDQE IDMGSLNPGK QLFEKMISGM YMGelVRLIL VKMAKEELLF GGKLSPELLN TGRFETKDIS DIEGEKDGIR KAREVLMRLG LDPTQEDCVA THRICQIVST RSASLCAATL AAVLQRIKEN KGEERLRSTI GVDGSVYKKH PHFAKRLHKT VRRLVPGCDV RFLRSEDGSG KGAAMVTAVA YRLADQHRAR QKTLEHLQLS HDQLLEVKRR MKVEMERGLS KETHASAPVK MLPTYVCATP DGTEKGDFLA LDLGGTNFRV LLVRVRNGKW GGVEMHNKIY AIPQEVMHGT GDELFDHIVQ CIADFLEYMG MKGVSLPLGF TFSFPCQQNS LDESILLKWT KGFKASGCEG EDVVTLLKEA IHRREEFDLD VVAVVNDTVG TMMTCGFEDP HCEVGLIVGT GSNACYMEEM RNVELVEGEE GRMCVNMEWG AFGDNGCLDD FRTEFDVAVD ELSLNPGKQR FEKMISGMYL GEIVRNILID FTKRGLLFRG RISERLKTRG IFETKFLSQI ESDCLALLQV RAILQHLGLE STCDDSIIVK EVCTVVARRA AQLCGAGMAA VVDRIRENRG LDALKVTVGV DGTLYKLHPH FAKVMHETVK DLAPKCDVSF LQSEDGSGKG AALITAVACR IREAGQR